Australia Artificial lungs Market Overview, 2031

The Australian artificial lungs-heart market is emerging as a niche yet critical segment within advanced biomedical devices, driven by the rising prevalence of chronic respiratory and cardiovascular diseases. Market performance is shaped by increasing demand for extracorporeal membrane oxygenation (ECMO) systems, artificial lung prototypes, and hybrid cardiopulmonary support devices, with growth supported by Australia’s strong hospital infrastructure and government investment in critical care technologies. Drivers of growth include the aging population, rising incidence of COPD and heart failure, and the need for alternatives to donor organ transplantation. The purpose and benefits of artificial lungs-heart systems lie in sustaining patients during acute respiratory or cardiac failure, bridging them to transplant or recovery, and reducing mortality in critical care settings. Historically, the market evolved from early heart-lung machines used in surgery to advanced ECMO systems and investigational bioartificial lungs. The scope of products now spans portable ECMO devices, implantable artificial lungs, and integrated cardiopulmonary assist systems. The scope of technology includes biocompatible membranes, microfluidics, magnetically levitated pumps, and AI-enabled monitoring platforms. Market components encompass device manufacturers, tertiary hospitals, research institutes, and government health agencies. Policies under the Therapeutic Goods Administration (TGA) emphasize safety, clinical validation, and ethical use in critical care. Challenges include high R&D costs, limited patient awareness, and the complexity of long-term implantation. Cultural trends and customer behavior show growing acceptance of advanced life-support technologies, with patients and families favoring minimally invasive, portable solutions. Connected to the parent global market, Australia aligns with Asia-Pacific’s rapid adoption of ECMO and artificial lung technologies, benefiting from global innovation pipelines and clinical collaborations.

According to the research report, "Australia Artificial lungs Overview, 2031," published by Bonafide Research, the Australia Artificial lungs is anticipated to grow at more than 7.8% CAGR from 2026 to 2031.The competitive landscape in Australia’s artificial lungs market features global leaders such as Medtronic, Getinge, and Xenios AG, alongside local innovators and research-driven institutions. Local players include CSIRO-backed biomedical research groups and university hospitals collaborating on bioartificial lung prototypes and ECMO advancements. Their products and services range from extracorporeal oxygenation systems to investigational implantable lungs, with USPs centered on biocompatibility, portability, and integration with telehealth monitoring. Business models combine direct hospital partnerships, distributor networks, and government-funded R&D initiatives. Price ranges vary ECMO systems can cost between AUD 80,000–150,000, while investigational implantable lungs are projected to exceed AUD 200,000, reflecting complexity and innovation. Market trends highlight miniaturization, wearable oxygenation devices, and AI-driven monitoring platforms. Opportunities lie in expanding critical care capacity, developing portable artificial lungs for home use, and leveraging Australia’s strong biomedical research ecosystem. Latest news includes collaborations between Australian universities and international firms to accelerate clinical trials of bioartificial lungs, as well as government-backed initiatives to enhance ECMO availability in tertiary hospitals. This competitive landscape underscores how Australia balances global imports with local innovation, positioning itself as a key contributor to next-generation respiratory support technologies. Local collaborations with The University of Sydney and Monash University are driving innovation in bioartificial lung scaffolds. Competitive differentiation is emerging through portable ECMO units, designed for rapid deployment in emergency and transport settings. Pricing strategies increasingly include leasing and bundled service models, making advanced devices more accessible to hospitals. Recently it was highlighted that Australia’s role is enhancing in Asia-Pacific ECMO training hubs, strengthening expertise and regional leadership in artificial lung technologies.

The Australian artificial lungs market is witnessing robust growth, driven by rising respiratory disease prevalence and technological innovation across multiple device categories. The market growth is supported by increasing demand for advanced life-support systems and transplant alternatives. Among technology segments, Extracorporeal Membrane Oxygenation (ECMO) systems dominate due to their critical role in managing acute respiratory distress syndrome (ARDS) and serving as a bridge-to-transplant solution. ECMO adoption is further supported by advancements in veno-arterial and veno-venous configurations that enhance patient survival rates. Artificial Lung Devices, including paracorporeal and implantable systems, are gaining traction as long-term support options for chronic lung disease patients, offering portability and improved quality of life. Heart-Lung Machines remain essential in surgical settings, particularly for cardiopulmonary bypass procedures, though their market share is relatively stable compared to newer technologies. Emerging innovations in Bioengineered Lung Tissues represent a transformative frontier, with research institutions in Australia exploring regenerative medicine approaches to reduce dependency on donor organs. Membrane Oxygenators continue to be widely used in both ECMO and heart-lung machines, with improvements in biocompatibility and efficiency driving adoption. Meanwhile, Ventricular Assist Devices with Oxygenation are evolving as hybrid solutions, combining circulatory and respiratory support for patients with complex cardiopulmonary conditions. Collectively, these segments reflect a dynamic ecosystem where traditional devices coexist with cutting-edge biohybrid systems, positioning Australia as a growing hub for artificial lung technologies. The interplay of clinical demand, government healthcare investments, and ongoing R&D ensures that each technology type contributes uniquely to market expansion, with ECMO and bioengineered tissues expected to lead future growth trajectories.

The Australian artificial lungs market is expanding rapidly, with end-user segmentation highlighting diverse adoption across healthcare facilities. The growth is currently driven by rising respiratory disease prevalence and increasing reliance on advanced life-support technologies. Hospitals and Medical Centres represent the largest end-user segment, accounting for the majority of demand due to their comprehensive infrastructure and ability to manage acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and post-surgical recovery cases. Cardiac Surgery Centres are significant adopters, utilizing artificial lungs and heart-lung machines during complex cardiothoracic procedures, ensuring patient safety during bypass operations. Emergency Care Facilities increasingly deploy portable ECMO and membrane oxygenators to stabilize patients in critical respiratory failure, reflecting the growing emphasis on rapid intervention technologies. Transplant Centres form a specialized niche, using artificial lungs as bridge-to-transplant solutions, reducing mortality rates among patients awaiting donor organs. Meanwhile, Specialized Intensive Care Units (ICUs) are key growth drivers, as they integrate advanced artificial lung devices for long-term respiratory support, particularly in cases of multi-organ failure or severe pulmonary hypertension. Finally, Ambulatory Surgical Centres are emerging as a smaller but growing segment, adopting compact oxygenation systems for minimally invasive procedures and short-term respiratory support. Collectively, these end-user categories illustrate a dynamic ecosystem where hospitals dominate, but specialized centres and emergency facilities are increasingly critical to market expansion. The interplay of clinical demand, government healthcare investments, and ongoing R&D ensures that artificial lung technologies are becoming indispensable across Australia’s healthcare continuum, with hospitals and ICUs expected to remain the primary growth anchors.

The Australian artificial lungs market is evolving rapidly, with application-based segmentation underscoring its diverse clinical utility across acute and chronic care settings. It is driven by rising respiratory disease prevalence, limited donor organ availability, and technological advancements in extracorporeal and implantable devices. Acute Care Applications dominate usage, particularly in managing acute respiratory distress syndrome (ARDS), pneumonia, and multi-organ failure, where ECMO and membrane oxygenators provide immediate life-saving support. Cardiac Surgery Support represents a critical segment, with heart-lung machines and oxygenation systems integrated into cardiopulmonary bypass procedures, ensuring safe surgical outcomes in complex thoracic operations. Emergency Resuscitation is an emerging application, as portable artificial lung devices and compact ECMO systems are increasingly deployed in trauma centres and emergency care facilities to stabilize patients in respiratory collapse. Bridge-to-Transplant Therapy is a growing niche, offering artificial lungs as interim solutions for patients awaiting donor organs, significantly reducing mortality rates and improving transplant readiness. Lung Transplantation Support further extends this role, with artificial lungs used perioperatively to optimize patient oxygenation and recovery. Finally, Chronic Respiratory Support is gaining traction, particularly among patients with end-stage COPD, pulmonary hypertension, or fibrosis, where long-term paracorporeal and bioengineered lung devices enhance quality of life and reduce hospital dependency. Collectively, these applications highlight a dynamic ecosystem where acute interventions coexist with long-term support strategies, positioning artificial lungs as indispensable tools across Australia’s healthcare continuum. With hospitals, ICUs, and transplant centres driving adoption, the interplay of clinical demand, government investment, and ongoing R&D ensures that acute care and bridge-to-transplant therapies will remain the primary growth anchors, while chronic support applications steadily expand their footprint.



Considered in this report
•Historic Year: 2020
•Base Year: 2025
•Estimated Year: 2026
•Forecast Year: 2031

Aspects covered in this report
• Australia Artificial Lungs Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top-profiled companies
• Strategic recommendation

By Technology Type
• Extracorporeal Membrane Oxygenation (ECMO)
• Artificial Lung Devices
• Heart-Lung Machines
• Bioengineered Lung Tissues
• Membrane Oxygenators
• Ventricular Assist Devices with Oxygenation

By End-User Type
• Hospitals and Medical Centres
• Cardiac Surgery Centres
• Emergency Care Facilities
• Transplant Centres
• Specialized Intensive Care Units
• Ambulatory Surgical Centres

By Application
• Acute Care Applications
• Cardiac Surgery Support
• Emergency Resuscitation
• Bridge-to-Transplant Therapy
• Lung Transplantation Support
• Chronic Respiratory Support